Rifamycin SV-MMX® as the recommended self-treatment for moderate to severe travellers' diarrhoea: reply
J Travel Med
.
2019 May 10;26(3):taz014.
doi: 10.1093/jtm/taz014.
Authors
Robert Steffen
1
,
Herbert L DuPont
2
Affiliations
1
University of Zurich, Epidemiology, Biostatistics and Prevention Institute, Hirschengraben 84, Zurich, CH, Switzerland.
2
The University of Texas-Houston School of Public Health and Medical School, Center for Infectious Diseases, 6720 Bertner MC1-164, Houston, TX, USA.
PMID:
30848824
PMCID:
PMC6509471
DOI:
10.1093/jtm/taz014
No abstract available
Publication types
Comment
MeSH terms
Bacteria
Ciprofloxacin*
Diarrhea
Humans
Rifamycins
Travel*
Substances
Rifamycins
Ciprofloxacin
rifamycin SV
Grants and funding
UL1 TR000371/TR/NCATS NIH HHS/United States